{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:55:31Z","timestamp":1790751331025,"version":"4.1.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union's Horizon 2020 research and innovation program","award":["847762"],"award-info":[{"award-number":["847762"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adjunctive host-directed therapies (HDT) may improve treatment outcomes in tuberculosis (TB). Affordable repurposed drugs can be quickly implemented in clinical practice; however, predictive biomarkers are essential for determining their potential effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>72 patients (35.2% people with HIV-1) from South Africa with drug-sensitive pulmonary TB, recruited to the SMA-TB clinical trial of adjunctive acetylsalicylic acid (ASA) and ibuprofen (IBU), were included. CD4+ T-cell subsets and Mtb-specific CD4+ T-cell responses were analyzed by flow cytometry at baseline, week 2, week 8 and week 24 and tested as predictors for microbiological, clinical and radiological outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most TB patients experienced a fast sputum culture conversion and good clinical and radiological outcomes by week 24, regardless of intervention or HIV coinfection. During TB therapy, fractions of Mtb-specific polyfunctional CD4+ T cells, Th1 and Th1\/Th17 subsets, and CD153 expression increased, whereas Ki67+ HLA-DR + CD4+ T cells declined. No statistically significant differences were identified between the ASA or IBU groups and placebo for any defined outcome. Still, higher baseline fractions of polyfunctional and CD153-expressing CD4+ T cells were associated with fast sputum culture conversion in the ASA and placebo arms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CD4+ T-cell subsets show promise as markers of disease severity and potential predictors of microbiological, clinical, and radiological outcomes in treated TB. However, the present findings are insufficient to support the routine use of ASA or IBU in adjunctive HDT regimens, and larger, targeted studies are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiag380","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:40:07Z","timestamp":1784893207000},"source":"Crossref","is-referenced-by-count":0,"title":["CD4+ T-Cell Markers Associated With Treatment Outcomes in Tuberculosis: A Sub-analysis of a Phase IIB Trial of Acetylsalicylic Acid and Ibuprofen as Adjunctive Therapy"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-7892","authenticated-orcid":false,"given":"Noelia","family":"Alonso-Rodr\u00edguez","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Oslo University Hospital , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5813-4197","authenticated-orcid":false,"given":"Iselin H\u00f8gbakk","family":"Edlund","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Oslo University Hospital , Oslo ,","place":["Norway"]},{"name":"Institute of Clinical Medicine, University of Oslo , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0395-047X","authenticated-orcid":false,"given":"Hans Christian Dalsbotten","family":"Aass","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8778-3577","authenticated-orcid":false,"given":"Chiara","family":"Sopegno","sequence":"additional","affiliation":[{"name":"Experimental TB Unit, Germans Trias I Pujol Research Institute (IGTP) , Badalona, Catalonia ,","place":["Spain"]},{"name":"Structural Bioinformatics Lab, Department of Medicine and Life Sciences,Universitat Pompeu Fabra , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0958-0510","authenticated-orcid":false,"given":"Judith","family":"Farr\u00e9s","sequence":"additional","affiliation":[{"name":"Experimental TB Unit, Germans Trias I Pujol Research Institute (IGTP) , Badalona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7014-1608","authenticated-orcid":false,"given":"Nino","family":"Gogichadze","sequence":"additional","affiliation":[{"name":"Experimental TB Unit, Germans Trias I Pujol Research Institute (IGTP) , Badalona, Catalonia ,","place":["Spain"]},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona , Bellaterra, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2469-8832","authenticated-orcid":false,"given":"Lilibeth","family":"Arias","sequence":"additional","affiliation":[{"name":"Experimental TB Unit, Germans Trias I Pujol Research Institute (IGTP) , Badalona, Catalonia ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Respiratorias (CIBERES) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7048-9740","authenticated-orcid":false,"given":"Kaori L","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Experimental TB Unit, Germans Trias I Pujol Research Institute (IGTP) , Badalona, Catalonia ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Respiratorias (CIBERES) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennedy","family":"Otwombe","sequence":"additional","affiliation":[{"name":"Perinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]},{"name":"School of Public Health, Faculty of Health Sciences, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8717-9039","authenticated-orcid":false,"given":"Ziyaad","family":"Waja","sequence":"additional","affiliation":[{"name":"Perinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tumelo","family":"Moloantoa","sequence":"additional","affiliation":[{"name":"Perinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Pillay","sequence":"additional","affiliation":[{"name":"Perinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thabiso","family":"Seiphetlo","sequence":"additional","affiliation":[{"name":"Perinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0184-5705","authenticated-orcid":false,"given":"Neil","family":"Martinson","sequence":"additional","affiliation":[{"name":"Perinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]},{"name":"Centre for TB Research, Department of Medicine, Johns Hopkins University , Baltimore ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2808-7270","authenticated-orcid":false,"given":"Cristina","family":"Vilaplana","sequence":"additional","affiliation":[{"name":"Experimental TB Unit, Germans Trias I Pujol Research Institute (IGTP) , Badalona, Catalonia ,","place":["Spain"]},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona , Bellaterra, Catalonia ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Respiratorias (CIBERES) , Madrid ,","place":["Spain"]},{"name":"Microbiology Department, Northern Metropolitan Clinical Laboratory, Hospital Universitari Germans Trias I Pujol , Badalona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4009-4032","authenticated-orcid":false,"given":"Anne Ma","family":"Dyrhol-Riise","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Oslo University Hospital , Oslo ,","place":["Norway"]},{"name":"Institute of Clinical Medicine, University of Oslo , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"2026093002014712100_jiag380-B1","volume-title":"Global tuberculosis report 2025","author":"Word Health Organization","year":"2025"},{"key":"2026093002014712100_jiag380-B2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1164\/rccm.202410-2096ST","article-title":"Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: an official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"211","author":"Saukkonen","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093002014712100_jiag380-B3","doi-asserted-by":"crossref","first-page":"170077","DOI":"10.1183\/16000617.0077-2017","article-title":"Tuberculosis and lung damage: from epidemiology to pathophysiology","volume":"27","author":"Ravimohan","year":"2018","journal-title":"Eur Respir Rev"},{"key":"2026093002014712100_jiag380-B4","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/S1473-3099(16)00078-5","article-title":"Host-directed therapies for infectious diseases: current status, recent progress, and future prospects","volume":"16","author":"Zumla","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2026093002014712100_jiag380-B5","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3389\/fimmu.2017.00772","article-title":"Non-steroidal anti-inflammatory drugs as host-directed therapy for tuberculosis: a systematic review","volume":"8","author":"Kroesen","year":"2017","journal-title":"Front Immunol"},{"key":"2026093002014712100_jiag380-B6","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3390\/pathogens11111291","article-title":"Host-directed therapies for Tuberculosis","volume":"11","author":"Jeong","year":"2022","journal-title":"Pathogens"},{"key":"2026093002014712100_jiag380-B7","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1073\/pnas.1424563112","article-title":"Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery","volume":"112","author":"Datta","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026093002014712100_jiag380-B8","doi-asserted-by":"crossref","first-page":"101672","DOI":"10.1016\/j.smim.2022.101672","article-title":"Inflammation-mediated tissue damage in pulmonary tuberculosis and host-directed therapeutic strategies","volume":"65","author":"Tiwari","year":"2023","journal-title":"Semin Immunol"},{"key":"2026093002014712100_jiag380-B9","doi-asserted-by":"crossref","first-page":"ftw012","DOI":"10.1093\/femspd\/ftw012","article-title":"Neutrophils in tuberculosis\u2013first line of defence or booster of disease and targets for host-directed therapy?","volume":"74","author":"Dallenga","year":"2016","journal-title":"Pathog Dis"},{"key":"2026093002014712100_jiag380-B10","doi-asserted-by":"crossref","first-page":"970408","DOI":"10.3389\/fmed.2022.970408","article-title":"Host-directed therapies in pulmonary tuberculosis: updates on anti-inflammatory drugs","volume":"9","author":"Cubillos-Angulo","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026093002014712100_jiag380-B11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/infdis\/jit152","article-title":"Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis","volume":"208","author":"Vilaplana","year":"2013","journal-title":"J Infect Dis"},{"key":"2026093002014712100_jiag380-B12","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/infdis\/jiz110","article-title":"Thrombocyte inhibition restores protective immunity to mycobacterial infection in zebrafish","volume":"220","author":"Hortle","year":"2019","journal-title":"J Infect Dis"},{"key":"2026093002014712100_jiag380-B13","volume-title":"WHO model list of essential medicines: 18th list (April 2013)","author":"World Health Organization","year":"2013"},{"key":"2026093002014712100_jiag380-B14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1186\/s13063-023-07448-0","article-title":"SMA-TB: study protocol for the phase 2b randomized double-blind, placebo-controlled trial to estimate the potential efficacy and safety of two repurposed drugs, acetylsalicylic acid and ibuprofen, for use as adjunct therapy added to, and compared with, the standard WHO recommended TB regimen","volume":"24","author":"Arias","year":"2023","journal-title":"Trials"},{"key":"2026093002014712100_jiag380-B15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/00365540701558698","article-title":"TBscore: signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course","volume":"40","author":"Wejse","year":"2008","journal-title":"Scand J Infect Dis"},{"key":"2026093002014712100_jiag380-B16","doi-asserted-by":"publisher","author":"Cuadras","DOI":"10.1101\/2025.02.14.25322286"},{"key":"2026093002014712100_jiag380-B17","unstructured":"Gogichadze N, Dyrhol-Riise AM, Farr\u00e9s J, et al \u00a0SMA-TB outcomes and variables analysis plan. Preprint at Available at: 10.5281\/ZENODO.15125747 (2025)."},{"key":"2026093002014712100_jiag380-B18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41385-020-0322-6","article-title":"Mycobacterium tuberculosis-specific CD4 T cells expressing CD153 inversely associate with bacterial load and disease severity in human tuberculosis","volume":"14","author":"Du Bruyn","year":"2021","journal-title":"Mucosal Immunol"},{"key":"2026093002014712100_jiag380-B19","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1189\/jlb.1211619","article-title":"IL-17 and IFN-\u03b3 expression in lymphocytes from patients with active tuberculosis correlates with the severity of the disease","volume":"91","author":"Jurado","year":"2012","journal-title":"J Leukoc Biol"},{"key":"2026093002014712100_jiag380-B20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1146\/annurev-immunol-032712-095939","article-title":"The immune response in tuberculosis","volume":"31","author":"O\u2019Garra","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"2026093002014712100_jiag380-B21","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.4049\/jimmunol.1101122","article-title":"Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load","volume":"187","author":"Day","year":"2011","journal-title":"J Immunol"},{"key":"2026093002014712100_jiag380-B22","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1176","article-title":"Disease extent and anti-tubercular treatment response correlates with Mycobacterium tuberculosis-specific CD4 T-cell phenotype regardless of HIV-1 status","volume":"9","author":"Riou","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"2026093002014712100_jiag380-B23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102178","article-title":"A subset of circulating blood mycobacteria-specific CD4 T cells can predict the time to Mycobacterium tuberculosis sputum culture conversion","volume":"9","author":"Riou","year":"2014","journal-title":"PLoS One"},{"key":"2026093002014712100_jiag380-B24","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jinf.2013.02.004","article-title":"IFN\u03b3\/TNF\u03b1 specific-cells and effector memory phenotype associate with active tuberculosis","volume":"66","author":"Petruccioli","year":"2013","journal-title":"J Infect"},{"key":"2026093002014712100_jiag380-B25","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/s41467-025-57819-1","article-title":"CD4 T cell dysfunction is associated with bacterial recrudescence during chronic tuberculosis","volume":"16","author":"Chang","year":"2025","journal-title":"Nat Commun"},{"key":"2026093002014712100_jiag380-B26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nm.2299","article-title":"Dominant TNF-\u03b1+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease","volume":"17","author":"Harari","year":"2011","journal-title":"Nat Med"},{"key":"2026093002014712100_jiag380-B27","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"2026093002014712100_jiag380-B28","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.4049\/jimmunol.178.8.5217","article-title":"Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load","volume":"178","author":"Millington","year":"2007","journal-title":"J Immunol"},{"key":"2026093002014712100_jiag380-B29","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/eji.201948283","article-title":"Improved Mycobacterium tuberculosis clearance after the restoration of IFN-\u03b3+ TNF-\u03b1+ CD4+ T cells: impact of PD-1 inhibition in active tuberculosis patients","volume":"50","author":"Kamboj","year":"2020","journal-title":"Eur J Immunol"},{"key":"2026093002014712100_jiag380-B30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40001-016-0242-9","article-title":"MTB-specific lymphocyte responses are impaired in tuberculosis patients with pulmonary cavities","volume":"22","author":"Wang","year":"2017","journal-title":"Eur J Med Res"},{"key":"2026093002014712100_jiag380-B31","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/eji.201040455","article-title":"Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection","volume":"40","author":"Caccamo","year":"2010","journal-title":"Eur J Immunol"},{"key":"2026093002014712100_jiag380-B32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011237","article-title":"Expanded polyfunctional T cell response to mycobacterial antigens in TB disease and contraction post-treatment","volume":"5","author":"Young","year":"2010","journal-title":"PLoS One"},{"key":"2026093002014712100_jiag380-B33","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/imr.12079","article-title":"HIV-associated chronic immune activation","volume":"254","author":"Paiardini","year":"2013","journal-title":"Immunol Rev"},{"key":"2026093002014712100_jiag380-B34","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1126\/science.277.5322.112","article-title":"Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease","volume":"277","author":"Autran","year":"1997","journal-title":"Science"},{"key":"2026093002014712100_jiag380-B35","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1097\/00002030-199912030-00008","article-title":"Activation of CD8 T cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection","volume":"13","author":"Dyrhol-Riise","year":"1999","journal-title":"AIDS"},{"key":"2026093002014712100_jiag380-B36","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ebiom.2015.03.005","article-title":"Latent and active tuberculosis infection increase immune activation in individuals co-infected with HIV","volume":"2","author":"Sullivan","year":"2015","journal-title":"EBioMedicine"},{"key":"2026093002014712100_jiag380-B37","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/ni1467","article-title":"Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells","volume":"8","author":"Acosta-Rodriguez","year":"2007","journal-title":"Nat Immunol"},{"key":"2026093002014712100_jiag380-B38","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jaci.2011.05.025","article-title":"Reduced T(H)1\/T(H)17 CD4 T-cell numbers are associated with impaired purified protein derivative-specific cytokine responses in patients with HIV-1 infection","volume":"128","author":"Clark","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"2026093002014712100_jiag380-B39","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41385-019-0226-5","article-title":"Therapeutic host-directed strategies to improve outcome in tuberculosis","volume":"13","author":"Young","year":"2020","journal-title":"Mucosal Immunol"},{"key":"2026093002014712100_jiag380-B40","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jac\/dkl486","article-title":"Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis","volume":"59","author":"Byrne","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2026093002014712100_jiag380-B41","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s42003-019-0530-3","article-title":"Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice","volume":"2","author":"Mortensen","year":"2019","journal-title":"Commun Biol"},{"key":"2026093002014712100_jiag380-B42","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-2007-996108","article-title":"Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis","volume":"23","author":"Schr\u00f6r","year":"1997","journal-title":"Semin Thromb Hemost"},{"key":"2026093002014712100_jiag380-B43","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/eji.202149549","article-title":"Platelets accumulate in lung lesions of tuberculosis patients and inhibit T-cell responses and Mycobacterium tuberculosis replication in macrophages","volume":"52","author":"La Manna","year":"2022","journal-title":"Eur J Immunol"},{"key":"2026093002014712100_jiag380-B44","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3390\/jcm8070923","article-title":"Use of antiplatelet agents and survival of tuberculosis patients: a population-based cohort study","volume":"8","author":"Lee","year":"2019","journal-title":"J Clin Med"},{"key":"2026093002014712100_jiag380-B45","doi-asserted-by":"crossref","first-page":"e33478","DOI":"10.7554\/eLife.33478","article-title":"A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults","volume":"7","author":"Mai","year":"2018","journal-title":"Elife"},{"key":"2026093002014712100_jiag380-B46","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/23744235.2020.1778177","article-title":"Aspirin enhances the clinical efficacy of anti-tuberculosis therapy in pulmonary tuberculosis in patients with type 2 diabetes mellitus","volume":"52","author":"Wang","year":"2020","journal-title":"Infect Dis (Lond)"},{"key":"2026093002014712100_jiag380-B47","doi-asserted-by":"crossref","first-page":"6774","DOI":"10.1038\/s41467-021-27029-6","article-title":"A phase I\/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients","volume":"12","author":"Jenum","year":"2021","journal-title":"Nat Commun"},{"key":"2026093002014712100_jiag380-B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-75148-9","article-title":"Adjunctive ibuprofen in pre-extensively drug-resistant and extensively drug-resistant tuberculosis: a phase IIA open-label pilot clinical trial","author":"Fonseca","year":"2026","journal-title":"Nat Commun"},{"key":"2026093002014712100_jiag380-B49","doi-asserted-by":"publisher","author":"Arias","DOI":"10.64898\/2025.12.01.25341191"},{"key":"2026093002014712100_jiag380-B50","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1172\/JCI83279","article-title":"Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response","volume":"125","author":"Adekambi","year":"2015","journal-title":"J Clin Invest"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag380\/70335627\/jiag380.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag380\/70335627\/jiag380.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:01:58Z","timestamp":1790748118000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/advance-article\/doi\/10.1093\/infdis\/jiag380\/8746691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":50,"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag380","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"jiag380"}}